-

Bausch + Lomb Publishes Update Presentation for the 41st Annual J.P. Morgan Healthcare Conference

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, has published a company update presentation designed to complement remarks that will be provided by management at 3:00 p.m. PT (6:00 p.m. ET) today, Jan. 9, 2023, during the 41st Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation provides an overview of the Company’s recent performance and achievements, and offers insight into future goals and catalysts for 2023 and beyond.

The presentation is available on the Investor Relations page of the Bausch + Lomb website at: https://ir.bausch.com/investors/events-presentations. A live webcast and audio archive of the event will also be available on the Investor Relations page of the Company’s web site.

About Bausch + Lomb

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with more than 12,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Twitter, LinkedIn, Facebook and Instagram.

Contacts

Investor:
Arthur Shannon
arthur.shannon@bausch.com

Allison Ryan
Allison.ryan@bausch.com
(877) 354-3705 (toll free)

Media:
Lainie Keller
lainie.keller@bausch.com
(908) 927-1198

Kristy Marks
kristy.marks@bausch.com
(908) 927-0683

Bausch + Lomb Corporation

NYSE:BLCO

Release Versions

Contacts

Investor:
Arthur Shannon
arthur.shannon@bausch.com

Allison Ryan
Allison.ryan@bausch.com
(877) 354-3705 (toll free)

Media:
Lainie Keller
lainie.keller@bausch.com
(908) 927-1198

Kristy Marks
kristy.marks@bausch.com
(908) 927-0683

More News From Bausch + Lomb Corporation

Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced progress in the development of BL1243 (tonabersat), an investigational oral treatment for dry age-related macular degeneration (AMD), following a constructive meeting with the U.S. Food and Drug Administration (FDA). The discussion provided greater clarity on the clinical development path for BL1243. If successf...

Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter financial results on Wednesday, Oct. 28, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the c...

Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced European CE Mark approval of SeeLyra, the company’s next generation femtosecond laser. One of the most compact femtosecond platforms available, SeeLyra provides surgeons precision and control when performing laser preparation for premium cataract, LASIK flap and corneal therapeutic surgeries while simultaneously...
Back to Newsroom